EN
Home/Answers/GLP-1 medicines for PCOS
ALLAll countries Medicines

Do tirzepatide and semaglutide work for PCOS?

What we checked17 sources, each one opened and linked to the sentence it supportsLast checked Nov 16, 2026 · Next review due Nov 16, 2027 · How we write
The short answer

Partly. In PCOS trials, GLP-1 medicines gave modest short-term weight loss, often with stomach side effects; evidence on periods, excess hair and fertility is thin. No label we checked for tirzepatide (Mounjaro, Zepbound) or semaglutide (Wegovy, Ozempic) lists PCOS as a use. The 2023 international PCOS guideline says semaglutide could be considered for higher weight.

Is tirzepatide or semaglutide approved for PCOS?

No. None of the labels we text-searched (US Zepbound, Mounjaro, Wegovy and Ozempic; EU Mounjaro and Wegovy) lists PCOS (polycystic ovary syndrome) as a use.1,2,3,4,5,6

The 2023 international PCOS guideline says liraglutide or semaglutide “could be considered” for higher weight in adults with PCOS, on top of active lifestyle change.7 It is a conditional recommendation based on expert consensus, as PCOS evidence was insufficient.7 Our US guide to whether to consider a GLP-1 medicine covers who the labels are for.

PCOS was renamed PMOS (polyendocrine metabolic ovarian syndrome) in May 2026; diagnosis and treatment are unchanged.8

How much weight did women with PCOS lose in trials?

Trials in women with PCOS found modest short-term weight loss, mostly with older GLP-1 medicines.9

A 2026 review pooled 11 randomised trials of exenatide, liraglutide, beinaglutide and dulaglutide.9 These medicines lowered BMI by 1.38 points more than comparison treatments.9 The authors rated this low certainty, with 8 of 11 trials at high risk of bias.9

In a 32-week trial of 82 women, weight fell 5.7% on liraglutide 3 mg a day and 1.4% on a dummy treatment (placebo).10

Two small open-label trials, where everyone knew their treatment, came from one Chinese team.11,12 Semaglutide 1 mg weekly plus metformin cut 6.1 kg in 16 weeks, against 2.3 kg on metformin alone.11 That dose is below Wegovy’s usual 2.4 mg.2 Tirzepatide (2.5 mg weekly for 4 weeks, then 5 mg) plus metformin cut 10.4 kg in 16 weeks, against 1.7 kg, in 60 women.12 A German placebo-controlled tirzepatide trial of 198 women expects to finish its main measurements in December 2028.13

The risks, in brief Nausea, vomiting, diarrhoea and constipation are common, mostly while the dose is being raised. The US Zepbound and Wegovy labels also warn of an inflamed pancreas (pancreatitis).1,2 Side effects and risks (US guide)

Do they help periods, excess hair or fertility in PCOS?

Evidence on periods, excess hair and fertility is thin: a 2026 review found too little data, and fertility results come from two small trials.9,11,12

In the liraglutide trial, the free androgen index (a measure of male-type hormones) fell on liraglutide and rose slightly on placebo.10 In both Chinese trials, adding semaglutide or tirzepatide to metformin brought back more women’s periods.11,12

After semaglutide, 35% had a natural pregnancy between weeks 16 and 40, against 15% on metformin alone.11 After tirzepatide, 11 of 28 did between weeks 25 and 48, against 4 of 28.12 For women trying to conceive, the guideline names letrozole as the first medicine to trigger ovulation.7

What are the downsides for women with PCOS?

Stomach side effects are common, the labels say to stop before a planned pregnancy, and in one large trial outside PCOS, two-thirds of lost weight returned within a year of stopping.2,5,14

In the US Wegovy weight trials, 44% had nausea, against 16% on placebo.2 In the liraglutide PCOS trial, stomach side effects affected 58.2%, against 18.5%.10 In the tirzepatide PCOS trial, one woman left with gallbladder inflammation (cholecystitis).12

The guideline calls for effective contraception when pregnancy is possible, as safety data in pregnancy are lacking.7 The US and EU Wegovy labels say to stop at least 2 months before a planned pregnancy, and the EU Mounjaro label at least 1 month.2,6,5 The US Zepbound label says tirzepatide may make the pill less reliable. It advises a non-pill method or a barrier for 4 weeks after starting and after each dose increase.1

That trial, STEP 1, gave semaglutide 2.4 mg to adults without diabetes.14

What do people with PCOS report on tirzepatide or semaglutide?

From public patient forums: 124 Reddit threads in r/Zepbound, r/mounjarouk, r/Mounjaro, r/Semaglutide, r/WegovyWeightLoss and r/WegovyPillWeightLoss, posts from October 2025 to October 2026. Personal reports, not medical evidence.

What people describe

  • Matches the trials Many say they lost weight with PCOS, on tirzepatide or semaglutide. PCOS trials found weight loss, mostly modest and short-term.9,12
  • Matches the trials Many say their periods returned or became regular. Two small trials found more cycles returning; a 2026 review judged the evidence insufficient.9,11,12
  • Matches the trials A few describe an unexpected pregnancy after their periods returned. Two small trials found more natural pregnancies, recorded after the GLP-1 medicine had stopped.11,12
  • Matches the trial Several say weight or symptoms came back after stopping. For weight, STEP 1 found two-thirds of the loss returned within a year of stopping semaglutide.14

Advice people share

  • Matches the labels Several advise planning when to stop before trying to conceive, though a few say they kept taking it while trying. The EU labels say to stop at least 2 months before a planned pregnancy for semaglutide and 1 month for tirzepatide, and the US Zepbound label says to stop once pregnancy is recognised.6,5,1
  • Matches the US Zepbound label A few warn that tirzepatide may affect the pill. The US Zepbound label advises a non-pill method or a barrier for 4 weeks after starting and after each dose increase.1
  • Label says otherwise Several mention compounded or unregulated versions. The FDA says compounded drugs are not FDA-approved, and it does not review them for safety, effectiveness or quality before they are sold.17
  • Label says otherwise Several suggest doses or gaps between doses that differ from the label. The US Zepbound label sets once-weekly doses, raised in 2.5 mg steps after at least 4 weeks.1

In your country

The trial and guideline evidence is the same everywhere; the labels differ on tirzepatide and the pill, and we could not open every country’s label.

Australia

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill treated as not approved). Semaglutide tablets, diabetes: Rybelsus approved; whether supplied not confirmed.

Label: We could not open Australia’s Product Information, so this page relies on the US, EU and UK labels. These differ on the pill: the US Zepbound and UK Mounjaro labels advise a non-pill method or a barrier for 4 weeks after starting tirzepatide and after each dose increase; the EU label says no change is needed.1,5,15

Emergency number: 000

Should I consider a GLP-1 medicine? Guide for Australia

Canada

Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen, Zepbound. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Semaglutide Injection (Dr. Reddy’s; shortage reported Jul 2026, lots recalled Aug 2026); Apo-Semaglutide (one lot recalled Aug 2026). Semaglutide tablets, weight: none (no oral Wegovy in Health Canada’s drug database). Semaglutide tablets, diabetes: Rybelsus. Semaglutide approved but not marketed: Sevmia, Poviztra, Plosbrio, Aspen-Semaglutide, Semaglutide Injection (Aspen), Sandoz Semaglutide.

Label: We could not open Canada’s product monographs, so this page relies on the US, EU and UK labels. These differ on the pill: the US Zepbound and UK Mounjaro labels advise a non-pill method or a barrier for 4 weeks after starting tirzepatide and after each dose increase; the EU label says no change is needed.1,5,15

Emergency number: 911

Should I consider a GLP-1 medicine? Guide for Canada

France

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill not sold in France). Semaglutide tablets, diabetes: none found (Rybelsus not in France’s medicines database).

Label: The EU Mounjaro product information says no change to the pill is needed with tirzepatide, unlike the US Zepbound label. It says to stop tirzepatide at least 1 month before a planned pregnancy.5

Emergency number: 15 or 112

Should I consider a GLP-1 medicine? Guide for France

Germany

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy Tablette. Semaglutide tablets, diabetes: Rybelsus.

Label: The EU Mounjaro product information says no change to the pill is needed with tirzepatide, unlike the US Zepbound label. It says to stop tirzepatide at least 1 month before a planned pregnancy.5

Emergency number: 112

Should I consider a GLP-1 medicine? Guide for Germany

India

Sold as: Tirzepatide: Mounjaro, Yurpeak. Semaglutide injection, weight: Wegovy; Poviztra; Noveltreat. Semaglutide injection, diabetes: Ozempic; Obeda (Dr Reddy’s; recalled Jul 2026 over an active-ingredient impurity; on 23 Oct 2026 the company said it planned to relaunch in Nov; resumption not confirmed at 8 Nov 2026; distributors told Reuters it may be discontinued); Sematrinity; GLIPIQ; Semalix (batches recalled Jul 2026); Semanat; Semafull. Semaglutide injection, diabetes and weight: Semaglyn; Mashema; Alterme; Semasize; Obesema; Hepaglide. Semaglutide, diabetes and weight (form not confirmed): Obeda Pro; Obeda Plus (Dr Reddy’s, made by Hetero Labs; in the market from late Jul 2026). Semaglutide injection, use not confirmed: Semanext; Livarise; Sundae. Semaglutide, form and use not confirmed: Samakind; Usema (batches recalled). Semaglutide tablets, weight: not confirmed. Semaglutide tablets, diabetes: Rybelsus; Sembolic; Obeda (tablets not part of the Jul 2026 recall).

Label: We could not find or open an Indian label, so this page relies on the US, EU and UK labels. These differ on the pill: the US Zepbound and UK Mounjaro labels advise a non-pill method or a barrier for 4 weeks after starting tirzepatide and after each dose increase; the EU label says no change is needed.1,5,15

Emergency number: 112

Should I consider a GLP-1 medicine? Guide for India

Saudi Arabia

Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Tasylev; Lugyda; Glucentra. Semaglutide tablets, weight: none (Wegovy pill not registered). Semaglutide tablets, diabetes: Rybelsus.

Label: We could not find or open a Saudi label, so this page relies on the US, EU and UK labels. These differ on the pill: the US Zepbound and UK Mounjaro labels advise a non-pill method or a barrier for 4 weeks after starting tirzepatide and after each dose increase; the EU label says no change is needed.1,5,15

Emergency number: 997 or 911

Should I consider a GLP-1 medicine? Guide for Saudi Arabia

United Arab Emirates

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Rybelsus.

Label: We could not find or open a UAE label, so this page relies on the US, EU and UK labels. These differ on the pill: the US Zepbound and UK Mounjaro labels advise a non-pill method or a barrier for 4 weeks after starting tirzepatide and after each dose increase; the EU label says no change is needed.1,5,15

Emergency number: 998 for an ambulance, or 999

Should I consider a GLP-1 medicine? Guide for the United Arab Emirates

United Kingdom

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy tablets (authorised 11 Jun 2026; retail sale not confirmed). Semaglutide tablets, diabetes: Rybelsus.

Label: The UK Mounjaro SmPC gives the 4-week pill advice for women with obesity or overweight. It says to stop tirzepatide at least 1 month before a planned pregnancy.15

Emergency number: 999

Should I consider a GLP-1 medicine? Guide for the United Kingdom

United States

Sold as: Tirzepatide: Zepbound, Mounjaro. Semaglutide injection, weight: Wegovy, including Wegovy HD 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Ozempic tablets; Rybelsus (being discontinued).

Label: This page uses the US Zepbound, Mounjaro, Wegovy and Ozempic labels, so the US facts above apply directly.

Emergency number: 911

Should I consider a GLP-1 medicine? Guide for the United States

Get help now: call your local emergency number if you have stomach pain that started suddenly and is severe, which the NHS treats as an emergency.16 Emergency numbers: 911 in the US and Canada, 999 in the UK, 998 or 999 in the UAE, 000 in Australia, 112 in India and Germany, 15 or 112 in France, 997 or 911 in Saudi Arabia.

Contact your prescriber or a doctor right away if you have persistent or severe stomach pain, sometimes spreading to your back, which the US Zepbound and Wegovy labels link to an inflamed pancreas (acute pancreatitis).1,2 Do the same if you find you are pregnant, because the US Zepbound label says to stop once pregnancy is recognised.1

Read the full picture

Related questions

Did this answer your question?

Sources

  1. Eli Lilly. Zepbound (tirzepatide) prescribing information, US label: §1, §2, §5.5, §7, §8.1. pi.lilly.com/us/zepbound-uspi.pdf
  2. Novo Nordisk. Wegovy (semaglutide) prescribing information, US label: §1, §2, §5.2, §6 Table 3, §8.3. novo-pi.com/wegovy.pdf
  3. Eli Lilly. Mounjaro (tirzepatide) prescribing information, US label (searched for PCOS). pi.lilly.com/us/mounjaro-uspi.pdf
  4. Novo Nordisk. Ozempic (semaglutide) prescribing information, US label (searched for PCOS). novo-pi.com/ozempic.pdf
  5. European Medicines Agency. Mounjaro product information (EU label): §4.5, §4.6. ema.europa.eu (PDF)
  6. European Medicines Agency. Wegovy product information (EU label): §4.6. ema.europa.eu (PDF)
  7. Teede HJ, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Hum Reprod 2023;38(9):1655–1679. Recommendations 4.5.1, 5.3.1. Declared interests: one author declares speaker fees from Novo Nordisk (paper’s own declaration). Full text
  8. healthdirect (Australian Government). Polycystic ovarian syndrome (PCOS). healthdirect.gov.au
  9. Forslund M, et al. GLP-1 receptor agonist treatment in women with polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Endocrinol 2026;194(3):S25–S39. DOI
  10. Elkind-Hirsch KE, et al. Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled phase 3 study. Fertil Steril 2022;118:371–381. We read the abstract. DOI
  11. Chen H, et al. A prospective, randomized, open-label clinical trial of combined metformin and semaglutide therapy in overweight or obese women with polycystic ovary syndrome. Reprod Biol Endocrinol 2025;23:108. Registration ChiCTR2400090908. We read the abstract. DOI
  12. Yang Z, et al. Short-term combined treatment with tirzepatide and metformin for overweight/obese Chinese women with polycystic ovary syndrome: a prospective, open-label, randomised controlled trial. Diabetes Obes Metab 2026;28(8):7380–7392. Single centre (Chongqing); registration ChiCTR2400090908. DOI · Full text
  13. ClinicalTrials.gov. NCT07326111: A clinical trial of tirzepatide in subjects with overweight or obesity and PCOS-related ovarian dysfunction (PERIODS). University of Bonn. clinicaltrials.gov
  14. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab 2022;24:1553–1564. DOI
  15. Mounjaro KwikPen (tirzepatide) Summary of Product Characteristics, UK label: §4.5, §4.6. electronic Medicines Compendium
  16. NHS (UK). Stomach ache. nhs.uk
  17. US Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Content current as of Oct 1, 2026. fda.gov

Last checked Nov 16, 2026 · Next review due Nov 16, 2027 · Report an error

How this answer was made. Written by the GLP Guidebook team from the sources above, checked between Nov 9 and Nov 16, 2026. The “What people report” section summarises public patient forum posts we read; it is not medical evidence, and we never pass on advice that goes against the label. It’s general information, not medical advice. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call your local emergency number. How we write